Literature DB >> 29387468

The Future Role of Cardio-oncologists.

Radek Pudil1.   

Abstract

Cardiovascular (CV) disease and cancer remain the two most common causes of mortality in developed countries; however, progress in the treatment of malignant diseases significantly improved survival of oncological patients. Similarly, there is an increased number of the patients with malignancy who have a history of CV disease or an increased CV risk. Rates of CV problems from cancer-related therapeutics are high, and cardiotoxicity is the second most common cause of morbidity and mortality in cancer survivors. Therefore, there is a need for the development of an efficient programme to manage the problem of cardiotoxicity with the aim to decrease morbidity and mortality in patients and to improve their quality of life. For this purpose, cardio-oncological clinics should be an essential part of the strategy.

Entities:  

Keywords:  Cardiotoxicity; cardio-oncology clinic; detection; management; risk factors

Year:  2017        PMID: 29387468      PMCID: PMC5739898          DOI: 10.15420/cfr.2017:16:1

Source DB:  PubMed          Journal:  Card Fail Rev        ISSN: 2057-7540


  15 in total

Review 1.  Cardiac disease and heart failure in cancer patients: is our training adequate to provide optimal care?

Authors:  Carol L Chen; Richard Steingart
Journal:  Heart Fail Clin       Date:  2011-05-20       Impact factor: 3.179

2.  Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial.

Authors:  Mark Ledwidge; Joseph Gallagher; Carmel Conlon; Elaine Tallon; Eoin O'Connell; Ian Dawkins; Chris Watson; Rory O'Hanlon; Margaret Bermingham; Anil Patle; Mallikarjuna R Badabhagni; Gillian Murtagh; Victor Voon; Leslie Tilson; Michael Barry; Laura McDonald; Brian Maurer; Kenneth McDonald
Journal:  JAMA       Date:  2013-07-03       Impact factor: 56.272

3.  Cancer statistics, 2015.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-01-05       Impact factor: 508.702

4.  The prevention of cardiovascular disease in cancer survivors.

Authors:  Iyad N Daher; Tina R Daigle; Nirmanmoh Bhatia; Jean-Bernard Durand
Journal:  Tex Heart Inst J       Date:  2012

Review 5.  Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.

Authors:  Michel G Khouri; Pamela S Douglas; John R Mackey; Miguel Martin; Jessica M Scott; Marielle Scherrer-Crosbie; Lee W Jones
Journal:  Circulation       Date:  2012-12-04       Impact factor: 29.690

Review 6.  Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.

Authors:  Wei-Xiang Qi; Zan Shen; Li-Na Tang; Yang Yao
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

Review 7.  Developing a Comprehensive Cardio-Oncology Program at a Cancer Institute: The Moffitt Cancer Center Experience.

Authors:  Michael G Fradley; Allen C Brown; Bernadette Shields; Federico Viganego; Rongras Damrongwatanasuk; Aarti A Patel; Gregory Hartlage; Natalee Roper; Julie Jaunese; Larry Roy; Roohi Ismail-Khan
Journal:  Oncol Rev       Date:  2017-07-18

Review 8.  Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.

Authors:  Adriana Albini; Giuseppina Pennesi; Francesco Donatelli; Rosaria Cammarota; Silvio De Flora; Douglas M Noonan
Journal:  J Natl Cancer Inst       Date:  2009-12-10       Impact factor: 13.506

9.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).

Authors:  Jose Luis Zamorano; Patrizio Lancellotti; Daniel Rodriguez Muñoz; Victor Aboyans; Riccardo Asteggiano; Maurizio Galderisi; Gilbert Habib; Daniel J Lenihan; Gregory Y H Lip; Alexander R Lyon; Teresa Lopez Fernandez; Dania Mohty; Massimo F Piepoli; Juan Tamargo; Adam Torbicki; Thomas M Suter
Journal:  Eur Heart J       Date:  2016-08-26       Impact factor: 29.983

10.  Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.

Authors:  Erin J Aiello Bowles; Robert Wellman; Heather Spencer Feigelson; Adedayo A Onitilo; Andrew N Freedman; Thomas Delate; Larry A Allen; Larissa Nekhlyudov; Katrina A B Goddard; Robert L Davis; Laurel A Habel; Marianne Ulcickas Yood; Catherine McCarty; David J Magid; Edward H Wagner
Journal:  J Natl Cancer Inst       Date:  2012-09-05       Impact factor: 13.506

View more
  6 in total

Review 1.  Detection of radiation induced cardiotoxicity: Role of echocardiography and biomarkers.

Authors:  Radek Pudil
Journal:  Rep Pract Oncol Radiother       Date:  2020-02-24

Review 2.  Advanced Imaging Modalities to Monitor for Cardiotoxicity.

Authors:  Andreas Seraphim; Mark Westwood; Anish N Bhuva; Tom Crake; James C Moon; Leon J Menezes; Guy Lloyd; Arjun K Ghosh; Sarah Slater; Heather Oakervee; Charlotte H Manisty
Journal:  Curr Treat Options Oncol       Date:  2019-08-08

3.  Healthcare disparities in cardio oncology: patients receive same level of surveillance regardless of race at a safety net hospital.

Authors:  Crystal B Chen; Raj K Dalsania; Eman A Hamad
Journal:  Cardiooncology       Date:  2021-01-25

4.  Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Patients With Breast Cancer: Protocol for a Multi-Institutional Prospective Study.

Authors:  Giulia Borgonovo; Elen Vettus; Alessandra Greco; Laura Anna Leo; Francesco Fulvio Faletra; Catherine Klersy; Moreno Curti; Mariacarla Valli
Journal:  JMIR Res Protoc       Date:  2022-04-21

5.  Physiological monitoring in the complex multi-morbid heart failure patient - Introduction.

Authors:  Giuseppe M C Rosano; Petar M Seferović
Journal:  Eur Heart J Suppl       Date:  2019-12-31       Impact factor: 1.803

Review 6.  Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree?

Authors:  Balaraman Kalyanaraman
Journal:  Redox Biol       Date:  2019-11-26       Impact factor: 11.799

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.